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Identity 
Other names: SCFR (Stem Cell Factor Receptor); 
CD117 
HGNC (Hugo): KIT 
Location: 4q12 
Local order: centromere-PDGFRA-KIT-KDR-
telomere. 
 
KIT (4q12) - Courtesy Mariano Rocchi, Resources for Molecular 
Cytogenetics. 
 
 
 
 
 
DNA/RNA 
Description 
Spans 89 kb; 21 exons; size of intron 1: 37,4 kb. 
Transcription 
5,23 kb mRNA; alternative splicing of exon 9 gives rise 
to two isoforms, KitA and Kit, that differ by the 
presence or absence of four aminoacids. 
Protein 
Description 
976 aa; 145 kDa; type III receptor tyrosine kinase; 
contains an extracellular domains with 5 Ig-like loops, 
a highly hydrophobic transmenbrane domain (23 aa), 
and an intracellular domain with tyrosine kinase 
activity split by a kinase insert (KI) in an ATP-binding 
region and in the phosphotransferase domain. 
Expression 
Hematopoietic stem cells, mast cells, melanocytes, 
germ-cell lineages and ICCs (Interstitial cells of Cajal). 
Localisation 
Plasma membrane. 
Function 
SCF/MGF receptor with tyrosine kinase activity; 
binding of ligand (SCF) induces receptor dimerization, 
autophosphorylation and signal transduction via 
molecules containing SH2- domains. 
Homology 
With CSF-1R, PDGFRb, PDGFRa, and FLT3. 
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Mutations 
Note: See diagrams: Loss-of-function mutations, and 
Gain-of-function mutations. 
Germinal 
In piebaldism, and in familial gastrointestinal stromal 
tumours (see below). 
Somatic 
In aggressive mastocytosis, mast cell leukemia, ANLL 
with/without mast cell involvement, myeloproliferative 
disorders, colon carcinoma and gastrointestinal stromal 
tumours and germ cell tumors (GCCs). 
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Implicated in 
Piebaldism 
Disease 
Autosomal dominant disorder of pigmentation; loss of 
function abnormalities of the c-kit gene have been 
demonstrated in 59% of the typical patients. 
Familial gastrointestinal stromal 
tumours and sporadic gastrointestinal 
stromal tumours (GISTs) 
Disease 
GISTs are the most common mesenchymal tumors in 
the human digestive tract; they originate from kit-
expressing cells (ICCs), and often have activating c-kit 
mutations clustered in the juxtamembrane domain. 
Systemic mast cell disease (SMCD) 
Disease 
Mast cell hyperplasia in the bone marrow, liver, spleen, 
lymph nodes, gastrointestinal tract and skin; gain of 
function mutations are detected in most patients. 
Prognosis 
Depending on the four clinical entities recognized: 
indolent form, form associated with hematologic 
disorder, aggressive SMCD and mast cell leukemia; 
leukemic transformation with mast cell involvement is 
characterized by rapid progression of disease with a 
survival time less than 1 year. 
Oncogenesis 
Clinical features of malignant hematopoietic cell 
growth are influenced by the time, the location of c-kit 
mutative events, and the number of associated lesions. 
Core binding factor leukemias (ANLL-
M2 with t(8;21) (link), (ANLL-M4Eo with 
inv(16)) 
Disease 
Characterized by disruption and loss of CBFa2/AML1 - 
CBFb/PEBP2b function. 
Myelomonoblastic leukemia cells are marked by 
combined positivity for the stem cell antigens CD34, 
CD117 and high frequency of c-kit mutations (see 
Figure on CBF leukemia and KIT mutations). 
To be noted 
Note 
Loss of expression of c-KIT appears to be associated 
with progression of some tumors (melanoma) and 
autocrine/paracrine stimulation of the c-kit/SCF system 
may participate in human solid tumors such as lung, 
breast, testicular and gynecological malignancies. 
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